Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Ablative Solutions, Inc. is a medical device company focused on developing innovative solutions for the treatment of hypertension. Founded in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company specializes in endovascular catheters, particularly the Peregrine System. This catheter allows for the minimally invasive delivery of therapeutic agents into the perivascular space surrounding peripheral blood vessels. Ablative Solutions offers an alternative to surgical renal denervation, providing a safe, effective, and cost-efficient method to address hypertension and related conditions caused by an overactive sympathetic nervous system. The company aims to meet the significant medical need for effective treatments for patients with poorly controlled hypertension.
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
Developer of an invasive device designed for the treatment of benign prostatic hyperplasia. The company's device provides treatment for the enlargement of the prostate gland that causes difficulty with urination by placing the device inside the urethra to restore function that ensures normal urination, enabling hospitals to help patients get cured of the disease.
Spire, Inc., also known as Spire Health, develops health-tracking devices and remote patient monitoring solutions aimed at managing respiratory chronic diseases. Founded in 2013 and based in San Francisco, the company specializes in continuous respiration sensing and offers ambulatory monitoring services. Its technology includes an activity tracker that monitors physical movement, breathing patterns, and sleep, providing insights into inhalation and exhalation times, apneic events, and daily activities. Spire Health's solutions cater to various health conditions, including chronic obstructive pulmonary disease, congestive heart failure, asthma, sleep disorders, and anxiety. By leveraging advanced algorithms and sensors, Spire Health aims to empower patients and healthcare providers with actionable data to improve health outcomes and overall well-being.
KLIFO provides end-to-end expert capabilities, enabling partners to maximise opportunity, mitigate risks, drive innovation and achieve efficient project advancement. The company offers multidisciplinary consulting and operational solutions spanning all clinical research areas, clinical trial supply, QA, CMC development, regulatory affairs, pharmacovigilance, and the development of pharmaceutical and biotech products and medical devices.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Acti-Med is a manufacturer specializing in medical technology, focusing on the development and production of high-quality cannulas and cannula systems for the medical and pharmaceutical sectors. The company provides a range of products, including skin punches, curettes, and spinal cannulas, tailored to meet the needs of clients in oncology, pain therapy, pharmaceuticals, and veterinary medicine. Acti-Med emphasizes compliance with stringent regulatory standards, ensuring that its medical components and devices are designed to meet the specific requirements of its customers.
LUMICKS B.V. is a company that specializes in developing advanced equipment for dynamic single-molecule and cell avidity analysis, facilitating research in biology and cancer at the molecular and cellular levels. Founded in 2014 and headquartered in Amsterdam, with an additional office in Cambridge, Massachusetts, LUMICKS offers innovative technologies such as correlative optical tweezers-fluorescence microscopy systems and the C-Trap, which integrates optical tweezers with advanced imaging techniques. The company’s Acoustic Force Spectroscopy (AFS) enables the study of mechanical properties in biological systems, while its u-Flux microfluidics system allows for single-molecule experiments in controlled laminar flow environments. By enabling live measurements and imaging of molecular interactions, LUMICKS provides valuable insights into the fundamental causes of diseases, including cancer, and supports drug optimization efforts.
Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, founded in 2017. The company specializes in targeted protein degradation technology, which is aimed at developing innovative cancer therapeutics. Amphista's approach leverages the body's natural processes to selectively degrade and eliminate proteins that contribute to disease progression. By advancing next-generation therapeutics, the company seeks to improve treatment efficacy and enhance patient outcomes across a range of diseases. Amphista's research focuses on identifying novel methods to modulate the cell's degradation machinery, thereby addressing the underlying mechanisms of various conditions.
Volta Medical is a start-up based in Marseille, France, that specializes in developing artificial intelligence software for interventional cardiology, particularly focusing on the treatment of atrial fibrillation, the most common cardiac arrhythmia. Founded in 2016, the company has created AIFib, its first AI software that enhances the functionality of mapping catheters used in the analysis of electrograms and the treatment of arrhythmias. Volta Medical aims to provide innovative solutions that assist cardiologists during interventional procedures, embodying expertise in both interventional cardiology and intracardiac signal analysis. The company's commitment to advancing its technology and products is reflected in its efforts to recruit top talent and its recognition from the European Commission, which awarded its technology a "Seal of Excellence."
Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative immune oncology biopharmaceuticals. Founded in 2016, the company specializes in a bispecific antibody platform designed to engage gamma-delta T cells, which play a crucial role in the immune response against cancer. Lava Therapeutics aims to create next-generation bispecific antibodies that not only activate and recruit the immune system but also enhance its ability to identify and eliminate tumor cells. The company's approach seeks to provide effective, safe, and cost-efficient treatments for both hematological and solid cancers, empowering healthcare professionals to better harness the body's immune capabilities in the fight against cancer.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, that specializes in developing and selling innovative hearing aids for individuals experiencing hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, addressing common barriers to hearing aid adoption such as cost, accessibility, and social stigma. The company provides online hearing screenings and virtual support, allowing customers to receive assistance without needing in-person visits. Eargo's products are available for purchase online or over the phone, and the company emphasizes personalized consultations with licensed hearing professionals through various communication channels. By offering its solutions at approximately half the cost of traditional hearing aids, Eargo aims to enhance the quality of life for people with hearing impairments.
Withings is a developer of digital health and wellness devices aimed at empowering individuals to make informed health decisions. The company offers a diverse range of products, including smart scales that help users achieve fitness and weight goals, stylish activity trackers, hybrid smartwatches, and an advanced sleep-tracking mat. Additionally, Withings provides medically accurate devices for monitoring blood pressure and temperature, allowing users to effectively track their health progress. These products facilitate data sharing with healthcare professionals, promoting a collaborative approach to personal health management.
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.
Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.
Eetgemak BV, established in 2006 and located in Katwijk, the Netherlands, specializes in the production of ready-made meals tailored for various sectors, including healthcare and education. The company offers a diverse range of chilled and frozen meal options, including regular, biological, vegetarian, and multicultural dishes, as well as specialized dietary meals. Its clientele consists of hospitals, nursing homes, residential care centers, home care organizations, schools, daycare centers, and catering establishments. Eetgemak’s products are designed to support the nutritional needs and well-being of patients and residents, ensuring that meals are both convenient and health-conscious.
Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.
Ablative Solutions, Inc. is a medical device company focused on developing innovative solutions for the treatment of hypertension. Founded in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company specializes in endovascular catheters, particularly the Peregrine System. This catheter allows for the minimally invasive delivery of therapeutic agents into the perivascular space surrounding peripheral blood vessels. Ablative Solutions offers an alternative to surgical renal denervation, providing a safe, effective, and cost-efficient method to address hypertension and related conditions caused by an overactive sympathetic nervous system. The company aims to meet the significant medical need for effective treatments for patients with poorly controlled hypertension.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative immune oncology biopharmaceuticals. Founded in 2016, the company specializes in a bispecific antibody platform designed to engage gamma-delta T cells, which play a crucial role in the immune response against cancer. Lava Therapeutics aims to create next-generation bispecific antibodies that not only activate and recruit the immune system but also enhance its ability to identify and eliminate tumor cells. The company's approach seeks to provide effective, safe, and cost-efficient treatments for both hematological and solid cancers, empowering healthcare professionals to better harness the body's immune capabilities in the fight against cancer.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Inari Medical is a commercial-stage medical device company headquartered in Irvine, California, established in 2011. The company specializes in developing innovative products for the treatment of venous diseases, particularly focusing on venous thromboembolism. Inari Medical has created two key minimally invasive devices: the ClotTriever, designed for the removal of blood clots from peripheral blood vessels in patients with deep vein thrombosis, and the FlowTriever, which is used to treat pulmonary embolism. Both systems are 510(k)-cleared by the FDA, allowing for effective clot removal without the need for thrombolytic drugs. Inari Medical aims to enhance the quality of life for patients suffering from these conditions, with the majority of its revenue generated from the United States and additional contributions from international markets.
Performation Healthcare Intelligence is a provider of healthcare specific business intelligence solutions to monitor costs, processes and quality. The company supports clients in taking well-informed decisions that contribute to the delivery of high quality and effective care. With over a hundred enthusiastic consultants and business intelligence experts, Performation is a leading player in the Dutch market.
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, develops innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and now a subsidiary of Zambon S.p.A., the company focuses on combining novel formulations of existing drugs with advanced inhalation technologies. Their products include a liposomal formulation of cyclosporine A designed for inhalation, paired with a high-performance nebulizer that optimizes drug delivery. This approach allows for rapid delivery of high drug concentrations directly to the lungs, enhancing the efficacy of treatments while reducing systemic exposure. Breath Therapeutics aims to address significant unmet medical needs in rare pulmonary conditions through its targeted inhalation therapies.
LUMICKS B.V. is a company that specializes in developing advanced equipment for dynamic single-molecule and cell avidity analysis, facilitating research in biology and cancer at the molecular and cellular levels. Founded in 2014 and headquartered in Amsterdam, with an additional office in Cambridge, Massachusetts, LUMICKS offers innovative technologies such as correlative optical tweezers-fluorescence microscopy systems and the C-Trap, which integrates optical tweezers with advanced imaging techniques. The company’s Acoustic Force Spectroscopy (AFS) enables the study of mechanical properties in biological systems, while its u-Flux microfluidics system allows for single-molecule experiments in controlled laminar flow environments. By enabling live measurements and imaging of molecular interactions, LUMICKS provides valuable insights into the fundamental causes of diseases, including cancer, and supports drug optimization efforts.
Nyxoah S.A. is a health-technology company based in Mont-Saint-Guibert, Belgium, focused on developing innovative solutions for treating sleep-disordered breathing, particularly obstructive sleep apnea (OSA). Founded in 2009, Nyxoah has created the Genio system, a CE-Mark validated bilateral neuro-stimulation therapy designed for patients with moderate to severe OSA. The company aims to improve the quality of life for OSA sufferers by offering a less cumbersome alternative to traditional devices and complex surgeries. Its technology features a tiny, battery-less implantable neurostimulator that targets the nerves of the tongue to prevent airway blockage, stimulating the muscles only when necessary. This approach not only reduces costs and simplifies implantation but also minimizes the risk of device migration. By collaborating with leading experts in sleep disorders, Nyxoah is dedicated to advancing neurostimulation devices that can significantly enhance the lives of those affected by OSA.
NightBalance B.V., founded in 2009 and based in The Hague, the Netherlands, develops and markets innovative solutions for the treatment of positional obstructive sleep apnea (OSA). The company's primary product, the Sleep Position Trainer (SPT), continuously monitors a patient's sleep behavior and delivers gentle vibrations to prompt them to change their position when they turn onto their back, thereby minimizing disruptions to their natural sleep patterns. NightBalance originated from research conducted at Delft University of Technology, where efforts to enhance positional therapy for sleep apnea began in 2007. The company operates as a subsidiary of Koninklijke Philips N.V., focusing on improving patient comfort and sleep quality through its smart therapy solutions.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Private Equity Round in 2016
NIZO food research BV provides contract research and food innovation services for dairy, food and beverage, ingredients, and biotech industries worldwide. It offers analysis, contract research, production, Webinar, white paper, training, and pre-competitive research program services; and proteins, bacteria, and processing solutions. The company also rents a flex office. NIZO food research BV was founded in 1948 and is headquartered in Ede, the Netherlands with additional offices in the United States, France, and Japan.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
BionX Medical Technologies, based in Bedford, Massachusetts, specializes in manufacturing advanced prosthetic devices aimed at enhancing the mobility and quality of life for individuals with amputations. The company’s flagship product, the BiOM Ankle, utilizes sophisticated technology, including powerful microprocessors and environmental sensors, to evaluate and adjust ankle position and stiffness dynamically. This bionic solution provides active amputees with a near-normal gait and reduces energy expenditure compared to traditional passive prosthetics. BionX serves its customers through a network of prosthetists and physicians both domestically and internationally. Established in 2007 and formerly known as iWalk, Inc., the company rebranded in 2015 and operates as a subsidiary of Otto Bock HealthCare GmbH.
Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Zetacom is a systems integrator based in the Netherlands, specializing in communication solutions for healthcare institutions, government bodies, corporates, and small to medium enterprises. The company is a market leader in healthcare-specific communication systems, with approximately 25% of hospitals and care institutions in the country utilizing its services. Zetacom offers a range of products including business telephony, care alarm systems, voice over WLAN, mobile telephony, and Unified Communications. Additionally, it is involved in the installation and maintenance of network infrastructures, telecommunication systems, and network security solutions. With a workforce of 140 employees, Zetacom operates from its headquarters in Zoetermeer and a southern office in 's-Hertogenbosch, ensuring that it delivers reliable and cost-effective communication systems tailored to the needs of its clients.
Private Equity Round in 2015
Zetacom is a systems integrator based in the Netherlands, specializing in communication solutions for healthcare institutions, government bodies, corporates, and small to medium enterprises. The company is a market leader in healthcare-specific communication systems, with approximately 25% of hospitals and care institutions in the country utilizing its services. Zetacom offers a range of products including business telephony, care alarm systems, voice over WLAN, mobile telephony, and Unified Communications. Additionally, it is involved in the installation and maintenance of network infrastructures, telecommunication systems, and network security solutions. With a workforce of 140 employees, Zetacom operates from its headquarters in Zoetermeer and a southern office in 's-Hertogenbosch, ensuring that it delivers reliable and cost-effective communication systems tailored to the needs of its clients.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Private Equity Round in 2015
Novicare provides nursing homes the opportunity to outsource their (para) medical staff. Novicare works with multidisciplinary self-managed teams that boost the quality of the (para) medical care. Novicare treats clients with complex and chronic conditions. Novicare also offers care to people at home under its brand VitaalThuis. Finally, Novicare offers its expertise to nursing homes by providing education, interim management and consultancy.
Novicare employs geriatricians, psychologists, physiotherapists, occupational therapists, speech therapists and dieticians.
The services of Novicare are characterized by its expertise, transparency, well-defined products and a high involvement in the patients.
Levicept Ltd. is a biotechnology company based in Sandwich, United Kingdom, founded in 2012. The company focuses on developing innovative biological therapies for chronic pain management, specifically targeting conditions such as osteoarthritis and neuropathic pain. Levicept is advancing a novel therapy, LEVI-04 (p75NTR-Fc), which aims to restore neurotrophin homeostasis by stabilizing binding proteins for excess neurotrophins associated with chronic pain states. This approach seeks to address the significant unmet medical need for safe and effective analgesics, particularly given the limitations and adverse effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs). Levicept is currently progressing LEVI-04 into phase I clinical trials to evaluate its safety and efficacy in patients with osteoarthritis.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Definiens specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostics, and healthcare sectors. The company offers software that delivers comprehensive readouts from whole tissue slides, cell-based assays, and full-body scans, enabling the correlation of this data with information from other sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating insights that enhance decision-making in research, diagnostics, and therapy. The company's mission is to advance research, contribute to the development of personalized medicine, and improve patient quality of life. Headquartered in Munich, Germany, Definiens also maintains offices across the United States.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Viroclinics Biosciences is a prominent contract research organization that specializes in virology testing and provides a comprehensive suite of diagnostic and preclinical services. The company focuses on improving human and animal health by supporting the biopharmaceutical sector in the development of vaccines, antibodies, antiviral compounds, and other therapies. With a strong emphasis on respiratory viruses, particularly influenza, Viroclinics offers expert advice on antiviral and vaccine development, along with traditional virology assays and advanced deep sequencing protocols for a wide array of viruses. Their BSL2 and BSL3 laboratories are equipped to conduct analyses in accordance with international ISO 15189 accreditation standards. By collaborating closely with the Erasmus MC Viroscience lab, Viroclinics leverages a wealth of experience and expertise, enhancing the quality and efficacy of its services in both clinical trials and preclinical research.
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.
Acacia Pharma is a hospital pharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of supportive care drugs for patients undergoing surgery, invasive procedures, or cancer treatments. The company’s lead product, BAREMSIS, is an intravenous formulation of amisulpride designed to prevent and treat post-operative nausea and vomiting. Other notable products include APD403, which has completed Phase II trials for chemotherapy-induced nausea and vomiting, and BYFAVO, an ultra-short-acting intravenous benzodiazepine anesthetic that has completed Phase III trials for use in procedures like colonoscopy and bronchoscopy. Acacia Pharma primarily serves anesthesiologists and oncologists, with a focus on addressing issues related to nausea, vomiting, cancer-related fatigue, and cachexia. Established in 2006, the company continues to innovate in the field of cancer supportive care.
Private Equity Round in 2012
Pharmaline is an innovative compounding pharmacy located in Oldenzaal, established in 2009 and now employing over 140 staff. The company adheres to the latest Good Manufacturing Practices (GMP) and provides a comprehensive range of pharmaceutical solutions to approximately 700 pharmacists in the Netherlands. Pharmaline specializes in both stock and ad hoc preparations, offering a diverse array of products including creams, ointments, tablets, capsules, liquids, and injectables. Their mission focuses on enhancing the quality of care while minimizing healthcare costs. The pharmacy's experienced pharmacists are readily available to offer expert advice on various aspects of pharmacotherapy, production engineering, application engineering, and regulatory compliance. Pharmaline is equipped with modern technology to support its operations, ensuring efficient and reliable pharmaceutical services.
Definiens specializes in image analysis and data mining solutions tailored for quantitative digital pathology within the life sciences, diagnostics, and healthcare sectors. The company offers software that delivers comprehensive readouts from whole tissue slides, cell-based assays, and full-body scans, enabling the correlation of this data with information from other sources. By automating analysis workflows, Definiens assists pharmaceutical and biotechnology firms, research institutions, clinical service organizations, and pathologists in generating insights that enhance decision-making in research, diagnostics, and therapy. The company's mission is to advance research, contribute to the development of personalized medicine, and improve patient quality of life. Headquartered in Munich, Germany, Definiens also maintains offices across the United States.
BionX Medical Technologies, based in Bedford, Massachusetts, specializes in manufacturing advanced prosthetic devices aimed at enhancing the mobility and quality of life for individuals with amputations. The company’s flagship product, the BiOM Ankle, utilizes sophisticated technology, including powerful microprocessors and environmental sensors, to evaluate and adjust ankle position and stiffness dynamically. This bionic solution provides active amputees with a near-normal gait and reduces energy expenditure compared to traditional passive prosthetics. BionX serves its customers through a network of prosthetists and physicians both domestically and internationally. Established in 2007 and formerly known as iWalk, Inc., the company rebranded in 2015 and operates as a subsidiary of Otto Bock HealthCare GmbH.
Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.
Private Equity Round in 2012
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Inova Labs, Inc. is a medical device development and manufacturing company based in Austin, Texas, established in 2002. The company specializes in creating innovative direct patient care products, particularly focusing on respiratory support. Its flagship offerings include the LifeChoice oxygen concentrators, which are available in both stationary and portable models, designed to provide supplemental oxygen for patients with respiratory illnesses. The LifeChoice products feature a pulse mode system and cater to various oxygen flow needs. Inova Labs also provides essential accessories such as carrying cases, external batteries, and power adapters. The company's products are distributed through authorized providers, who sell them on their respective websites.
Private Equity Round in 2011
Fysius is a chain of clinics for patients with lower-back and related pains. The treatment methods and treatment aids, such as the OriGENE device, take advantage of the latest scientific insights. With over 10,000 treated patients annually, Fysius is the largest and most specialized clinic for back pain in the Netherlands.
ProFibrix B.V. is a biotech company founded in 2004 that specializes in the development and marketing of products for the hemostasis and regenerative medicine markets. The company’s primary product, Fibrocaps, is a dry powder topical hemostat and tissue sealant made from a combination of fibrinogen and thrombin, aimed at stopping acute and severe bleeding during surgical procedures or following traumatic injuries. ProFibrix also provides a sterilized single-use delivery device designed to apply Fibrocaps directly to the target tissue, minimizing disruption to the wound. The company’s products leverage human fibrinogen, a natural blood protein, to enhance hemostasis, blood clotting, and tissue repair.
Private Equity Round in 2011
VerzuimVitaal B.V. is a Dutch company that specializes in providing occupational health services aimed at managing employee absenteeism. Founded in 2011 and located in Woerden, the Netherlands, the company focuses on enhancing the vitality of organizations and their employees to reduce absenteeism costs. In addition to promoting employee wellness, VerzuimVitaal oversees the management of sick leave and the reintegration process for employees returning to work.
Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.
Acacia Pharma is a hospital pharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of supportive care drugs for patients undergoing surgery, invasive procedures, or cancer treatments. The company’s lead product, BAREMSIS, is an intravenous formulation of amisulpride designed to prevent and treat post-operative nausea and vomiting. Other notable products include APD403, which has completed Phase II trials for chemotherapy-induced nausea and vomiting, and BYFAVO, an ultra-short-acting intravenous benzodiazepine anesthetic that has completed Phase III trials for use in procedures like colonoscopy and bronchoscopy. Acacia Pharma primarily serves anesthesiologists and oncologists, with a focus on addressing issues related to nausea, vomiting, cancer-related fatigue, and cachexia. Established in 2006, the company continues to innovate in the field of cancer supportive care.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Private Equity Round in 2010
Stepping Stones & Home Care Ltd is the founder and owner of three small villas, residential care for demented and frail elderly who are no longer able to live independently.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
ProFibrix B.V. is a biotech company founded in 2004 that specializes in the development and marketing of products for the hemostasis and regenerative medicine markets. The company’s primary product, Fibrocaps, is a dry powder topical hemostat and tissue sealant made from a combination of fibrinogen and thrombin, aimed at stopping acute and severe bleeding during surgical procedures or following traumatic injuries. ProFibrix also provides a sterilized single-use delivery device designed to apply Fibrocaps directly to the target tissue, minimizing disruption to the wound. The company’s products leverage human fibrinogen, a natural blood protein, to enhance hemostasis, blood clotting, and tissue repair.
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that they identify.
Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.
FlowCardia, Inc. is a medical device company founded in 2002 to design and develop a portfolio of innovative, catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. Chronic Total Occlusions (CTOs) are considered one of the last major clinical challenges in interventional therapy. The historic absence of safe and effective CTO recanalization devices is a major reason a large number of patients are still referred to coronary and peripheral bypass surgery and lower limb amputation.
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.